Pirfenidone capsule, a new class I drug of Contini pharmaceutical, has been sold for 15 million yuan since it was put into production in March this year

It is understood that pirfenidone capsule is a kind of national first-class new drug developed and produced by Beijing kangdini Pharmaceutical Co., Ltd with independent intellectual property rights Since it was officially put into operation in March this year, as of November, it has produced 20000 bottles in total, with a total output value of 16 million yuan and a sales revenue of 15 million yuan, which has increased the company's total sales revenue by 275% year-on-year, and has successfully achieved leapfrog development It is estimated that the sales revenue will reach 20-30 million yuan by the end of this year In 2011, pirafenidone capsule obtained the new drug certificate issued by the State Food and drug administration, and obtained the drug approval number and production approval document in December 2013 In March 2014, it was officially produced and listed The industrialization of the drug effectively fills the gap in the treatment of "idiopathic pulmonary fibrosis" in China, and its listing breaks the current situation that there is no medicine for this disease At present, the sales of pirfenidone capsule has covered 28 provinces and autonomous regions in China, and has entered nearly 100 clinical medical institutions, providing drug treatment for thousands of patients with idiopathic pulmonary fibrosis, significantly reducing the patient's pain, significantly reducing the cost of treatment, and prolonging the survival period The drug is also registered and declared in Australia, New Zealand and Southeast Asia, and the raw materials of pirfenidone will be exported to Southeast Asia in small quantities Beijing Contini Pharmaceutical Co., Ltd., founded in 2002, is located in Linhe Industrial Development Zone, Shunyi District, Beijing Relying on the convenient domestic and foreign transportation of terminal 3 of capital airport, it has grown into a new modern pharmaceutical enterprise integrating research and development, production and sales In 2011, GNI group and Shanghai Ruixing Gene Technology Co., Ltd successively invested in Contini company, and introduced the national class 1.1 pulmonary fibrosis specific new drug, pirfenidone, so that the company's product line took a new strategic step.